雌激素受体β在乳腺癌中的表达  

Study on the clinical value of estrogen receptor β protein detection in fresh human breast cancer samples

作　　者：温险峰[1] 沈镇宙[1] 吴炅[1] 沈赞[1] 沈坤炜[1] 陆劲松[1] 邵志敏[1] 

机构地区：[1]复旦大学医学院肿瘤医院乳腺外科,上海200032

出　　处：《中华实验外科杂志》2002年第1期27-28,共2页Chinese Journal of Experimental Surgery

摘　　要：目的　研究人乳腺癌新鲜标本中ERβ蛋白检测的临床价值。 方法　用Westernblot法检测 86例乳腺癌手术标本中ERβ蛋白含量 ,分析它和临床病理生物学特性的关系。 结果　 86例乳腺癌中 ,ERβ蛋白低表达 5 3例 ,占 61.6% ;高表达 3 3例 ,占 3 8.4%。表达水平和患者的绝经状态、病理分级、PR水平以及PS2水平相关 (P <0 .0 5 ) ;和肿瘤直径、腋淋巴结状态、ERα水平无关 (P >0 .0 5 )。根据ERα和PR分组后 ,ERα + /PR +组的ERβ蛋白高表达比例低于ERα -/PR -组 (P <0 .0 5 )。其余各亚组间ERβ蛋白表达差异无显著性 (P >0 .0 5 )。Objective To evaluate the clinical value of estrogen receptor (ER)β protein detection in breast cancer patients.Methods Western blot was used to detect the protein expression of 86 fresh human breast cancer samples.ERα,PS2 and PR were analyzed by immunohistochemistry.Results Among 86 samples,53 (61.6%) had low ERβ expression and 33 (38.4%) high ERβ expression.The level of ERβ protein was correlated with menopause status,tumor grade,PR and PS2 level (P<0.05).There were no significant difference between ERβ protein level and tumor size,node status,ERα (P>0.05).Subgroup analysis showed that ERβ protein expression in ERα+/PR+ breast tumors was significantly less than ERα /PR groups (P<0.05).But no significant difference was found between other subgroups.Conclusion ERβ protein detection may act as a useful marker to predict resistance to endocrine therapy and poor prognosis.

关 键 词：乳腺肿瘤 雌激素受体Β 内分泌治疗 预后 耐药 

分 类 号：R737.9[医药卫生—肿瘤]